Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

Dec 9 2009

Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced that multiple clinical studies of the chemotherapy agent ABRAXANE^® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) will be presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), being held in San Antonio, Texas from December 9 to December 13. Clinical results from investigator-sponsored studies will be reported, including an ongoing study evaluating the combination of lapatinib and nab^®-paclitaxel for first-line treatment of HER2+ breast cancer. Additional presentations will highlight analyses of cost of care in metastatic breast cancer patients, as well as the correlation between specific genotypes and treatment response rates.

ABRAXANE is currently approved in the second-line treatment of metastatic breast cancer and Abraxis continues to study the potential of ABRAXANE in areas of high unmet patient needs.

Metastatic breast cancer, also known as stage IV, refers to cancer that has spread to distant organs. In the majority of metastatic breast cancer patients, the metastasis is diagnosed after a cancer has already been treated. However, in about six to ten percent of all breast cancer patients, the cancer has spread to distant organs at the time of the first diagnosis. In the United States, there are 155,000 women and men living with metastatic breast cancer.

Results to be presented at the meeting include:

-A Taxane total cost of care analysis: Results of private payor claims data in metastatic breast cancer (Abstract #1076) Poster Presentation 1076; Thursday, December 10, 2009, 5:30 p.m. – 7:30 p.m.; Exhibit Halls A-B

-Pilot neoadjuvant trial with combination of lapatinib and nab^®-paclitaxel in HER2+ breast cancer (Abstract #1091) Poster Presentation 1091; Thursday, December 10, 2009, 5:30 p.m.-7:30 p.m.; Exhibit Halls A-B

-The basal-like, luminal-like, and HER2-like genotype and the 70-gene signatures predictors of response to neoadjuvant chemotherapy (NCT) with docetaxel, doxorubicin, cyclophosphamide (TAC), or AC and nab^®-paclitaxel and carboplatin +/- trastuzumab (trast) as part of (NCT) in patients (pts) with stage II-III breast cancer [including inflammatory breast cancer (BC)]. (Abstract #2026) Poster Presentation 2026; Friday, December 11, 2009, 7:00 a.m. - 9:00 a.m., Exhibit Halls A-B